Suppression of telomerase activity as an indicator of drug-induced cytotoxicity against cancer cells: In vitro studies with fresh human tumor samples

Laboratory Investigation

Volumn 79, Issue 8, 1999, Pages 993-1005

  Faraoni, Isabella ^a,c   Graziani, Grazia ^a   Turriziani, Mario ^a   Masci, Giovanna ^a   Mezzetti, Maurizio ^d   Testori, Alessandro ^c   Veronesi, Umberto ^c   Bonmassar, Enzo ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; RIBONUCLEOPROTEIN; TELOMERASE;

ARTICLE; CANCER CELL; CANCER PATIENT; CELL DIFFERENTIATION; CELL DIVISION; CHEMOSENSITIVITY; DNA SYNTHESIS INHIBITION; DRUG CYTOTOXICITY; DRUG INDUCED DISEASE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERE;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; EPIRUBICIN; FLUOROURACIL; HUMANS; REPRODUCIBILITY OF RESULTS; TELOMERASE; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0032774738     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Albanell J, Han W, Mellado B, Gunawardane R, Scher HI, Dmitrovsky E, and Moore MA (1996). Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines. Cancer Res 56:1503-1508.
2. Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, Klimstra D, Venkatraman E, Moore MA, and Dmitrovsky E (1997). High telomerase activity in primary lung cancer: Association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 89:1609-1615.
3. Andreotti PE,. Cree IA, Kurbacher CM, Hartmann DM, Under D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M, Sartori C, and Bruckner HW (1995). Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: Clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55:5276-5282.
4. Balconi G, Broggini M, Erba E, D'Incalci M, Colombo N, Mangioni C, and Bertolero F (1988). Human ovarian tumors in primary culture: Growth, characterization and initial evaluation of the response to cis-platinum treatment in vitro. Int J Cancer 41:809-818.
5. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, and Ozols RF (1987). Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47:414-418.
6. Bellamy WT (1992). Prediction of response to drug therapy of cancer. A review of in vitro assays. Drugs 44:690-708.
7. Burger AM, Double JA, and Newell DR (1997). Inhibition of telomerase activity by cisplatin in human testicular cancer cell. Eur J Cancer 33:638-644.
8. Carey LA, Hedican CA, Henderson GS, Umbricht CB, Dome JS, Varon D, and Sukumar S (1998). Careful histological confirmation and microdissection reveal telomerase activity in otherwise telomerase-negative breast cancer. Clin Cancer Res 4:435-440.
9. Chabner BA, Allegra CJ, Curt GA, and Calabresi P (1996). Antineoplastic agents. In: Hardman JG, Limbird LE, editors in chief. Goodman & Gilman's The pharmacological basis of therapeutics, 9th ed. Ed. New York: McGraw-Hill, 1233-1287.
10. Counter CM, Gupta J, Harley CB, Leber B, and Bacchetti S (1995). Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85:2315-2320.
11. Cree IA and Kurbacher CM (1997). Individualizing chemotherapy for solid tumors - Is there any alternative? Anticancer Drugs 8:541-548.
12. Croce MV, Colussi AG, and Segal-Eiras A (1998). Assessment of methods for primary tissue culture of human breast epithelia. J Exp Clin Cancer Res 17:19-26.
13. Faraoni I, Turriziani M, Bonmassar E, De Vecchis L, and Graziani G (1996a). Development of a novel in vitro chemosensitivity assay: Telomerase as a possible marker of tumor cell survival. J Chemotherapy 8:394-398.
14. Faraoni I, Turriziani M, Graziani G, De Vecchis L, and Bonmassar E (1996b). Telomerase as a marker of tumor cell viability: A new approach for in vitro chemosensitivity assay? J Exp Clin Cancer Res 15:311-312.
15. Faraoni I, Turriziani M, Masci G, De Vecchis L, Shay JW, Bonmassar E, and Graziani G (1997). Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro. Clin Cancer Res 3:579-585.
16. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Grider CW, and Villeponteau B (1995). The RNA component of human telomerase. Science 269:1236-1241.
17. Györf T and Herlyn M (1994). Melanocyte and melanoma cell lines. In: Hay RJ, editor. The atlas of human tumor cell lines. San Diego: Academic Press, 413-428.
18. Hansen MB, Nielsen SE, and Berg K (1989). Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210.
19. Harley C, Futcher A, and Greider C (1990). Telomeres shorten during aging of human fibroblasts. Nature 345:458-460.
20. Hathcock KS (1994). T cell enrichment by non-adherence to nylon. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, editors. Current protocols in immunology. New York: John Wiley & Sons, 3.2.1.
21. Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar AF, Hiyama K, Piatyszek MA, and Shay JW (1996). Telomerase activity in human breast tumors. J Natl Cancer Inst 88:116-122.
22. Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA, Shay JW, Ishioka S, and Yamakido M (1995). Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 155:3711-3715.
23. Jehl F, Quoix E, Leveque D, Pauli G, Breillout F, Krikorian A, and Monteil H (1991). Pharmacokinetics and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Cancer Res 51:2073-2076.
24. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, and Shay JW (1994). Specific association of human telomerase activity with immortal cell and cancer. Science 266:2011-2015.
25. Krupp G, Kuhne K, Tamm S, Klapper W, Heidorn K, Rott A, and Parwaresch R (1997). Molecular basis of artifacts in the detection of telomerase activity and a modified primer for a more robust 'TRAP' assay. Nucleic Acids Res 25:919-921.
26. Kyo S, Takakura M, Tanaka M, Murakami K, Saitoh R, Hirano H, and Inoue M (1998). Quantitative differences in telomerase activity among malignant, premalignant and benign ovarian lesions. Clin Cancer Res 4:399-405.
27. Morin GB (1989). The human telomerase terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59:521-529.
28. Norton JC, Holt SE, Wright WE, and Shay JW (1998). Enhanced detection of human telomerase activity. DNA Cell Biol 17:217-219.
29. Nugent CI and Lundblad V (1998). The telomerase reverse transcriptase: Components and regulation. Genes Dev 12: 1073-1085.
30. Park KH, Rha SY, Kim CH, Kim TS, Yoo NS, Kim JH, Roh JK, Non SH, Min JS, Lee KS, Kim BS, and Chung HC (1998). Telomerase activity and telomere lengths in various cell lines: Changes of telomerase activity can be another method for chemosensitivity evaluation. Int J Oncol 13:489-495.
31. Piatyszek MA, Kim NW, Weinrich SL, Hiyama K, Hiyama E, Hiyama E, Wright WE, and Shay JW (1995). Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci 17:1-15.
32. Shay JW, Woodring E, and Wright E (1996). Telomerase activity in human cancer. Curr Opin Oncol 8:66-71.
33. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
34. Taylor RS, Ramirez RD, Ogoshi M, Chaffins M, Piatyszek MA, and Shay JW (1996). Detection of telomerase activity in malignant and nonmalignant skin conditions. J Invest Dermatol 106:559-565.
35. Untch M, Sevin BU, Perras JP, Angioli R, Untch A, Hightower RD, Koechli O, and Averette HE (1994). Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxelcisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gynecol Oncol 53:44-49.
36. Villa R, Zaffaroni N, Folini M, Martelli G, De Palo G, Daidone MG, and Silvestrini R (1998). Telomerase activity in benign and' malignant breast lesions: A pilot prospective study on fine-needle aspirates. J Natl Cancer Inst 90:537-539.
37. Wan M, Li WZ, Duggan BD, Felix JC, Zhao Y, and Dubeau L (1997). Telomerase activity in benign and malignant epithelial ovarian tumors. J Natl Cancer Inst 89:437-441.
38. Wright WE, Shay JW, and Piatyszek MA (1995). Modifications of telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res 23:3794-3795.
39. Yasumoto S, Kunimura C, Kikuchi K, Tahara H, Ohji H, Yamamoto H, Ide T, and Utakoji T (1996). Telomerase activity in normal human epithelial cells. Oncogene 13:433-439.
40. Yoshida K, Sugino T, Goodison S, Warren BF, Nolan D, Wadsworth S, Mortensen NJ, Toge T, Tahara E, and Tarin D (1997). Detection of telomerase activity in exfoliated cancer cells in colonic luminal washings and its related clinical implications. Br J Cancer 75:548-553.